Advanced Search

 

Study ID Status Title Patient Level Data
49653/162 Completed A 26-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Rosiglitazone in Combination with Glibenclamide Compared to Normal Upward Titration of Glibenclamide in Patients with Type 2 Diabetes Mellitus
49653/163 Completed A Single Dose Study to Assess the Safety, Tolerability and Bioequivalence of the 2 x 2 mg versus the 4 mg Commercial Tablet Formulations of Rosiglitazone in Healthy Male Japanese Volunteers
49653/166 Completed Evaluation of Safety and Pharmacokinetics of Single Dose of Rosiglitazone in Healthy Korean Male Volunteers
49653/171 Completed An open-label, non-comparative multi centre study to obtain further information on the efficacy and safety of rosiglitazone as monotherapy when administered to Asian patients with Type 2 Diabetes Mellitus.
49653/175 Completed A 12-Week Randomized, Double-Blind, Multicenter, Parallel Group Study to evaluate the Safety and Efficacy of Actos (30 mg od and 45mg od) in Patients with Type 2 Diabetes Mellitus
49653/177 Completed AVA-177: Avandia in daily practice.
49653/183 Completed A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Avandia™ XR and AVANDIA™ (4mg BD) in Patients with Type 2 Diabetes Study Listed on ClinicalStudyDataRequest.com
49653/185 Completed Rosiglitazone Evaluation: Advancing Canadian Treatment of Type 2 Diabetes (REACT 2)
49653/203 Completed A post-marketing surveillance study of Avandia (Rosiglitazone) in the treatment of Filipino patients with type 2 diabetes
49653/206 Completed An open label, single center, randomized, cross-over study to determine the bioequivalence of the final market formulation of Rosiglitazone and the clinical trials formulation in Chinese subjects.
49653/207 Completed A 24-week Randomized, Double-blind, Active-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rosiglitazone When Administered to Pediatric Patients with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
49653/210 Completed An open-label, 16 weeks, non-comparative study to evaluate the efficacy and safety of Avandia (rosiglitazone) monotherapy, when administrated to patients with Type 2 Diabetes Mellitus (T2DM).
49653/211 Completed A 52-week double-blind study of the effect of rosiglitazone on cardiovascular structure and function in subjects with type 2 diabetes mellitus and congestive heart failure (NYHA class I/II) Study Listed on ClinicalStudyDataRequest.com
49653/224 Completed A Study to Examine the Effects of Alucol® , a Combination Magnesium/Aluminum Hydroxide-Containing Antacid, on the Pharmacokinetics of Rosiglitazone (8 mg). Study Listed on ClinicalStudyDataRequest.com
49653/225 Completed A Double-Blind Study to Assess the Effect of Rosiglitazone (RSG) on the Pharmacodynamics and Pharmacokinetics of Acenocoumerol in Healthy Male Volunteers Study Listed on ClinicalStudyDataRequest.com
49653/231_4yrfollowup Completed Observational Follow up of RECORD: Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes. A long-term, open-label, randomised study in patients with type 2 diabetes mellitus, comparing the combination of rosiglitazone and eit
49653/234 Completed A 26-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Rosiglitazone in Combination with Glimepiride compared to Glimepiride Alone in Patients with Type 2 Diabetes Mellitus.
49653/267 Completed A multi-center, open-label study to assess the safety and efficacy of rosiglitazone (RSG) as monotherapy or in combination therapy with concurrent Metformin (Met) or Sulphonylurea (SU) when administered to Chinese patients with Type 2 diabetes.
49653/267_1 Completed A multi-center, open-label extension study to assess the safety and efficacy of rosiglitazone as monotherapy or in combination with concurrent metformin or sulphonylurea therapy when administered to patients with type 2 diabetes.
49653/270 Completed A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone and Metformin (4 mg/500 mg) Compared to Concomitant Dosing of Rosiglitazone 4 mg and Metformin 500 mg Commercial Tablets-and a Dose Proportionality Study Comparing the 4 mg/500 mg and 1 mg/500 mg Combination Formulations. Study Listed on ClinicalStudyDataRequest.com
49653/271 Completed A Study to Assess the Effect of Food on the Pharmacokinetics of a Rosiglitazone 4mg and Metformin 500mg Combination Tablet Formulation and a Study Comparing the Pharmacokinetics of Rosiglitazone 4mg and Metformin 500mg Combination Tablet to Concomitant Dosing of Rosiglitazone 4mg and Metformin 500mg Commercial Tablets in the Fed State in Healthy Volunteers Study Listed on ClinicalStudyDataRequest.com
49653/282 Completed A Double-Blind Feasibility Study to Estimate and Compare the Effect of Rosiglitazone in Parallel with Glyburide on Cognition in Patients with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
49653/284 Completed A 24-Week Randomized, Double-blind, Double-Dummy, Multicenter Study to Compare the Efficacy of AVANDIA when added to Submaximal Doses of Metformin and to Compare the Tolerability of the Combination to Metformin Monotherapy when Administered to Subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
49653/292 Completed A Randomized, Double-Blind, Placebo-Controlled Trial to Assess Three Dose Levels of Rosiglitazone Maleate in the Treatment of Moderate to Severe Plaque Psoriasis. Study Listed on ClinicalStudyDataRequest.com
49653/295 Completed AVA-295: Avandia in daily practice.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.